本页面由Tiger Trade Technology Pte. Ltd.提供服务

康乃德生物医药

0.9057
+0.03574.10%
盘后:0.91000.0043+0.47%19:53 EDT
成交量:161.98万
成交额:148.29万
市值:5,702.64万
市盈率:-0.76
高:0.9330
开:0.9082
低:0.8800
收:0.8700
52周最高:3.82
52周最低:0.8501
股本:6,296.39万
流通股本:1,730.41万
量比:1.20
换手率:9.36%
股息:- -
股息率:- -
每股收益(TTM):-1.1933
每股收益(LYR):-1.0000
净资产收益率:-140.51%
总资产收益率:-69.75%
市净率:2.12
市盈率(LYR):-0.91

数据加载中...

2023/04/11

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/13

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/13

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/13

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/01/03

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/07/01

SEC问询函

CORRESP [Cover] - Correspondence
2022/07/01

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2022/06/17

SEC问询函

CORRESP [Cover] - Correspondence
2022/05/20

SEC问询函

CORRESP [Cover] - Correspondence
2022/03/31

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/25

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/25

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/15

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/14

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/06/07

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/03/29

超过5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/03/19

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2021/03/18

[修订]招股说明书

F-1/A [Amend] - Registration statement for certain foreign private issuers
2021/03/17

SEC问询函

CORRESP [Cover] - Correspondence